BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 24728294)

  • 21. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signatures of mutational processes in human cancer.
    Alexandrov LB; Nik-Zainal S; Wedge DC; Aparicio SA; Behjati S; Biankin AV; Bignell GR; Bolli N; Borg A; Børresen-Dale AL; Boyault S; Burkhardt B; Butler AP; Caldas C; Davies HR; Desmedt C; Eils R; Eyfjörd JE; Foekens JA; Greaves M; Hosoda F; Hutter B; Ilicic T; Imbeaud S; Imielinski M; Jäger N; Jones DT; Jones D; Knappskog S; Kool M; Lakhani SR; López-Otín C; Martin S; Munshi NC; Nakamura H; Northcott PA; Pajic M; Papaemmanuil E; Paradiso A; Pearson JV; Puente XS; Raine K; Ramakrishna M; Richardson AL; Richter J; Rosenstiel P; Schlesner M; Schumacher TN; Span PN; Teague JW; Totoki Y; Tutt AN; Valdés-Mas R; van Buuren MM; van 't Veer L; Vincent-Salomon A; Waddell N; Yates LR; ; ; ; ; Zucman-Rossi J; Futreal PA; McDermott U; Lichter P; Meyerson M; Grimmond SM; Siebert R; Campo E; Shibata T; Pfister SM; Campbell PJ; Stratton MR
    Nature; 2013 Aug; 500(7463):415-21. PubMed ID: 23945592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
    Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
    PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
    Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
    Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
    Cescon DW; Haibe-Kains B; Mak TW
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA replication stress: a source of APOBEC3B expression in breast cancer.
    Cescon DW; Haibe-Kains B
    Genome Biol; 2016 Sep; 17(1):202. PubMed ID: 27716362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
    Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations.
    Liu W; Wu J; Yang F; Ma L; Ni C; Hou X; Wang L; Xu A; Song J; Deng Y; Xian L; Li Z; Wang S; Chen X; Yin J; Han X; Li C; Zhao J; Cao G
    Clin Cancer Res; 2019 Sep; 25(18):5525-5536. PubMed ID: 31152021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
    Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
    Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.
    Warren CJ; Westrich JA; Doorslaer KV; Pyeon D
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28825669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational processes molding the genomes of 21 breast cancers.
    Nik-Zainal S; Alexandrov LB; Wedge DC; Van Loo P; Greenman CD; Raine K; Jones D; Hinton J; Marshall J; Stebbings LA; Menzies A; Martin S; Leung K; Chen L; Leroy C; Ramakrishna M; Rance R; Lau KW; Mudie LJ; Varela I; McBride DJ; Bignell GR; Cooke SL; Shlien A; Gamble J; Whitmore I; Maddison M; Tarpey PS; Davies HR; Papaemmanuil E; Stephens PJ; McLaren S; Butler AP; Teague JW; Jönsson G; Garber JE; Silver D; Miron P; Fatima A; Boyault S; Langerød A; Tutt A; Martens JW; Aparicio SA; Borg Å; Salomon AV; Thomas G; Børresen-Dale AL; Richardson AL; Neuberger MS; Futreal PA; Campbell PJ; Stratton MR;
    Cell; 2012 May; 149(5):979-93. PubMed ID: 22608084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
    Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
    Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
    Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.
    Seplyarskiy VB; Soldatov RA; Popadin KY; Antonarakis SE; Bazykin GA; Nikolaev SI
    Genome Res; 2016 Feb; 26(2):174-82. PubMed ID: 26755635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.
    Hoopes JI; Cortez LM; Mertz TM; Malc EP; Mieczkowski PA; Roberts SA
    Cell Rep; 2016 Feb; 14(6):1273-1282. PubMed ID: 26832400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring APOBEC3A protein levels in human cancer cells.
    Dananberg A; Maciejowski J
    Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
    Caswell D; Swanton C
    Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
    Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
    Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
    Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
    Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
    BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.